U.S., March 12 -- ClinicalTrials.gov registry received information related to the study (NCT06868667) titled 'Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma' on March 06.
Brief Summary: This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Japanese participants with relapsed refractory multiple myeloma.
Study Start Date: July 28, 2021
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: Belantamab mafodot...